Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis

BACKGROUND: Intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) is typically managed with transurethral resection of the bladder tumour (TURBT) followed by intravesical Bacillus Calmette–Guérin (BCG) immunotherapy; however, NMIBC patients can become refractory or unresponsive to BC...

Descripción completa

Detalles Bibliográficos
Autores principales: Quignot, Nadia, Jiang, Heng, Doobaree, Indraraj Umesh, Lehmann, Jan, Ghatnekar, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075214/
https://www.ncbi.nlm.nih.gov/pubmed/37035831
http://dx.doi.org/10.2147/CEOR.S398180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075214/
https://www.ncbi.nlm.nih.gov/pubmed/37035831
http://dx.doi.org/10.2147/CEOR.S398180

Ejemplares similares